FDA Issues Recall for Omnipod Insulin Pump Pods Over Tubing Defect Risk

4 min read|800 words

✓ Editorially Reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD — GMJ News Desk

The U.S. Food and Drug Administration (FDA) has issued a recall for certain Omnipod Pods manufactured by Insulet Corporation due to a potential tubing defect that may compromise insulin delivery. The defect involves a tear in the tubing that allows insulin to leak outside the pod rather than being delivered subcutaneously to patients with diabetes.

Key takeaways

Insulet Corporation initiated a recall of certain Omnipod Pods after discovering a manufacturing defect in tubing integrity
The tubing defect may cause insulin leakage, risking inadequate glycemic control for patients who rely on the device
The FDA advises affected patients to contact Insulet for replacement pods and to monitor blood glucose levels closely during the recall period

Tubing tear defect

Risk of insulin leakage from pod exterior rather than delivery to subcutaneous tissue, per FDA recall notice

Omnipod Recall: Insulin Delivery Pathway Disruption

When tubing integrity is compromised, insulin fails to reach the patient’s subcutaneous tissue, increasing hyperglycemia risk

100%

Normal insulin delivery path intact

Defect present

Tubing tear allows external leakage

Source: FDA Recall Notice, 2025 | Georgian Medical Journal News

Manufacturing Defect in Pod Tubing Integrity

According to the FDA recall announcement, certain Omnipod Pods manufactured by Insulet exhibit a defect where tubing may develop a tear during production or use. This defect allows insulin designated for subcutaneous infusion to escape the pod system, preventing proper insulin administration to patients. The tubing tear represents a critical failure in the drug delivery mechanism integral to the device’s safety and efficacy.

Submit Your Paper

Patients relying on affected Omnipod Pods face the dual risk of insulin leakage and inadequate insulin dosing, both of which can lead to acute hyperglycemic episodes and complications if undetected. The FDA classification of this defect indicates a significant risk to patient health warranting immediate corrective action.

Certain Omnipod Pods contain tubing defects that allow insulin to leak externally rather than deliver to the patient’s body, creating a direct risk of treatment failure and glycemic dyscontrol.

— U.S. Food and Drug Administration, 2025

Patient Action and Monitoring During Recall

The FDA advises all affected patients to contact Insulet Corporation directly to obtain replacement pods that have been verified to meet manufacturing specifications. Patients are instructed to increase blood glucose monitoring frequency during the transition period and to report any signs of inadequate insulin delivery, including unexplained elevated blood glucose readings or reduced insulin responsiveness.

This recommendation aligns with FDA quality and safety protocols for active medical device recalls. Insulet has committed to providing replacement pods and supporting patients throughout the recall process. Clinicians managing patients using Omnipod should review affected pod lot numbers and ensure patients understand the importance of enhanced glucose monitoring until replacement devices are in use.

Device Integrity and Clinical Implications

The Omnipod system represents a major innovation in insulin delivery, offering patients a tubeless, wearable pump that improves quality of life compared to traditional insulin injection therapy. The tubing defect identified in this recall underscores the critical importance of rigorous manufacturing quality control in insulin delivery devices. Any compromise in tubing integrity—whether from manufacturing error or material defect—directly translates to clinical failure and patient risk.

For clinicians, this recall highlights the need to verify device lot numbers against FDA recall databases and to counsel patients on appropriate interim management strategies. For a comprehensive overview of insulin pump safety standards, see our coverage of clinical device updates.

What this means

For patients: Contact Insulet immediately to identify whether your pod lot number is affected. Increase blood glucose monitoring to at least four times daily until replacement pods arrive. Watch for signs of insulin leakage (wet patches on the pod exterior) or unexplained high blood sugar readings. Do not delay—inadequate insulin delivery can lead to diabetic ketoacidosis if prolonged.

For clinicians: Review patient rosters for Omnipod users and cross-reference affected lot numbers against the FDA recall notice. Educate patients on interim glucose monitoring protocols and have backup insulin administration plans (pens, syringes) readily available. Consider temporary transition to multiple daily injections for high-risk patients if pod supply is disrupted.

For policymakers: This recall demonstrates the importance of post-market surveillance for insulin delivery devices. Ensure health systems have rapid communication channels with device manufacturers and FDA to identify and disseminate recall information. Review insurance coverage policies to ensure patients have seamless access to replacement devices during recalls without delay.

Looking Forward: Supply Chain Vigilance

Insulet Corporation’s rapid identification and initiation of the recall reflects appropriate post-market surveillance practices, though the incident raises important questions about upstream manufacturing quality assurance. As insulin pump adoption continues to grow globally, the clinical and public health community must remain vigilant about device integrity across all manufacturers. For updates on this recall and similar device safety alerts, monitor the FDA’s active recall database and consult your endocrinology care team for personalized guidance.

Source: FDA Medical Device Recall: Omnipod Insulin Pump Pods

Was this article helpful?